美国临床肿瘤学会——第46届年会

American Society of Clinical Oncology--46th annual meeting.

作者信息

Al-Shamahi Asma, Murch Lisa, Kirkham Konrad

机构信息

Thomson Reuters, London, UK.

出版信息

IDrugs. 2010 Aug;13(8):506-9.

PMID:20721815

Abstract

The 46th Annual Meeting of the American Society of Clinical Oncology, held in Chicago, included topics covering new therapeutic developments in the field of oncology. This conference report highlights selected presentations on novel therapies for cancers including glioblastoma, breast cancer, myeloma, NSCLC and solid tumors. Investigational drugs discussed include rindopepimut and PF-299804 (both Pfizer Inc), entinostat (Syndax Pharmaceuticals Inc), panobinostat and NVP-LDE-225 (both Novartis AG), CHR-3996 (Chroma Therapeutics Ltd), and HGS-1029 (Human Genome Sciences Inc).

摘要

在美国芝加哥举行的第46届美国临床肿瘤学会年会涵盖了肿瘤学领域新治疗进展的相关主题。本会议报告重点介绍了有关癌症新疗法的部分演讲，这些癌症包括胶质母细胞瘤、乳腺癌、骨髓瘤、非小细胞肺癌及实体瘤。所讨论的研究性药物包括rindopepimut和PF - 299804（均来自辉瑞公司）、恩替诺特（辛达克斯制药公司）、帕比司他和NVP - LDE - 225（均来自诺华公司）、CHR - 3996（Chroma Therapeutics有限公司）以及HGS - 1029（人类基因组科学公司）。